Literature DB >> 8972490

The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes.

J A Acosta1, L R Benzaquen, D J Goldstein, M T Tosteson, J A Halperin.   

Abstract

BACKGROUND: We have previously shown that the membrane attack complex (MAC) of complement stimulates cell proliferation and that insertion of homologous MAC into the membranes of endothelial cells results in the release of potent mitogens, including basic fibroblast growth factor (bFGF). The mechanism of secretion of bFGF and other polypeptides devoid of signal peptides, such as interleukin 1 (IL-1) is still an open problem in cell biology. We have hypothesized that the homologous MAC pore itself could constitute a transient route for the diffusion of biologically active macromolecules in and out of the target cells.
MATERIALS AND METHODS: Human red blood cell ghosts and artificial lipid vesicles were loaded with labeled growth factors, cytokines and IgG, and exposed to homologous MAC. The release of the 125I-macromolecules was followed as a function of time. The incorporation of labeled polypeptides and fluorescent dextran (MW: 10,000) was measured in MAC-impacted human red blood cells and human umbilical endothelial cells (HUVEC), respectively.
RESULTS: Homologous MAC insertion into HUVEC resulted in the massive uptake of 10-kD dextran and induced the release of bFGF, in the absence of any measurable lysis. Red blood cell ghosts preloaded with bFGF, IL-1 beta, and the alpha-chain of interferon-gamma (IFN-gamma) released the polypeptides upon MAC insertion, but they did not release preloaded IgG. MAC-impacted ghosts took up radioactive IFN-gamma from the extracellular medium. Vesicles loaded with IL-I released the polypeptide when exposed to MAC.
CONCLUSIONS: The homologous MAC pore in its nonlytic form allows for the export of cytosolic proteins devoid of signal peptides that are not secreted through the classical endoplasmic reticulum/Golgi exocytotic pathways. Our results suggest that the release, and perhaps the uptake, of biologically active macromolecules through the homologous MAC pore is a novel biological function of the complement system in mammals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972490      PMCID: PMC2230132     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  34 in total

1.  Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement.

Authors:  D W Michaels; A S Abramovitz; C H Hammer; M M Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

Review 2.  Control of the complement system.

Authors:  M K Liszewski; T C Farries; D M Lublin; I A Rooney; J P Atkinson
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

3.  Steady-state analysis of tracer exchange across the C5b-9 complement lesion in a biological membrane.

Authors:  P J Sims; P K Lauf
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

4.  Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation.

Authors:  J Torzewski; R Oldroyd; P Lachmann; C Fitzsimmons; D Proudfoot; D Bowyer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-05       Impact factor: 8.311

Review 5.  Physiology and pathophysiology of complement: progress and trends.

Authors:  B P Morgan
Journal:  Crit Rev Clin Lab Sci       Date:  1995       Impact factor: 6.250

6.  Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells.

Authors:  J A Halperin; A Taratuska; A Nicholson-Weller
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 7.  Complement in organ transplantation. Contributions to inflammation, injury, and rejection.

Authors:  W M Baldwin; S K Pruitt; R B Brauer; M R Daha; F Sanfilippo
Journal:  Transplantation       Date:  1995-03-27       Impact factor: 4.939

8.  Complement C5b-9 activates cytosolic phospholipase A2 in glomerular epithelial cells.

Authors:  A V Cybulsky; J C Monge; J Papillon; A J McTavish
Journal:  Am J Physiol       Date:  1995-11

9.  Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex.

Authors:  G L Stahl; W R Reenstra; G Frendl
Journal:  Circ Res       Date:  1995-04       Impact factor: 17.367

10.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells.

Authors:  L R Benzaquen; A Nicholson-Weller; J A Halperin
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  9 in total

1.  Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study.

Authors:  Jakob A Østergaard; Steffen Thiel; Peter Hovind; Charlotte B Holt; Hans-Henrik Parving; Allan Flyvbjerg; Peter Rossing; Troels K Hansen
Journal:  Diabetologia       Date:  2014-07-28       Impact factor: 10.122

2.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.

Authors:  K S Kilgore; E Schmid; T P Shanley; C M Flory; V Maheswari; N L Tramontini; H Cohen; P A Ward; H P Friedl; J S Warren
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 3.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

4.  A distinctive histidine residue is essential for in vivo glycation-inactivation of human CD59 transgenically expressed in mice erythrocytes: Implications for human diabetes complications.

Authors:  Rupam Sahoo; Pamela Ghosh; Michael Chorev; Jose A Halperin
Journal:  Am J Hematol       Date:  2017-09-08       Impact factor: 10.047

5.  A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Sonia Cantel; Amol Kavishwar; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

6.  DAF in diabetic patients is subject to glycation/inactivation at its active site residues.

Authors:  Rudolf Flückiger; Enzo Cocuzzi; Ram H Nagaraj; Menachem Shoham; Timothy S Kern; M Edward Medof
Journal:  Mol Immunol       Date:  2017-09-05       Impact factor: 4.407

7.  Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.

Authors:  Pamela Ghosh; Anand Vaidya; Rupam Sahoo; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

Review 8.  Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus.

Authors:  Kyumin Shim; Rayhana Begum; Catherine Yang; Hongbin Wang
Journal:  World J Diabetes       Date:  2020-01-15

9.  Inhibition of Complement Retards Ankylosing Spondylitis Progression.

Authors:  Chaoqun Yang; Peipei Ding; Qingkai Wang; Long Zhang; Xin Zhang; Jianquan Zhao; Enjie Xu; Na Wang; Jianfeng Chen; Guang Yang; Weiguo Hu; Xuhui Zhou
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.